Rochester General Hospital
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Rochester General Hospital sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Rochester General Hospital: 6 sponsored US clinical trials, none currently recruiting.
Rochester General Hospital sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 1 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Secondary Immune Deficiency Disorder, with 1 trials.
Upper-quartile sponsor footprint
Rochester General Hospital sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
6 total, page 1 of 1
Dynamic Change and Immune Response to Nasopharyngeal Carriage and Acute Otitis Media Pathogens
NCT04946084
Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig
NCT03730129
Dupilumab for Aspirin-exacerbated Respiratory Disease
NCT03595488
Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma
NCT02341209
Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig
NCT03211065
Oral Vancomycin for Preventing Clostridium Difficile Recurrence
NCT03200093
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 4 |
| Phase 4 | 1 |
Therapeutic Areas
How the Rochester General Hospital early-phase archive is shaped
6 indexed studies, none listed as recruiting (0% open); 3 completed (50%).
Phase mix: 1 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Secondary Immune Deficiency Disorder (1 trial), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Rochester General Hospital: archived-pipeline peers nationwide
Peers matched on 6 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Rochester General Hospital sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 archived trials
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
Related
What to do with this Rochester General Hospital page
6 registered trials is a research-attention snapshot, not an endorsement of Rochester General Hospital or any single study.
- None of Rochester General Hospital's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Secondary Immune Deficiency Disorder is the condition Rochester General Hospital studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Secondary Immune Deficiency Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Rochester General Hospital pipeline card: 6 registered trials from official public datasets.Report a data error.